ArticleScientific reports2019
Acute intraperitoneal infection with a hypervirulent Acinetobacter baumannii isolate in mice.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic Prospection of Animal Venoms-Derived Antimicrobial Peptides against Infections by Multidrug-ResistantToxins · 2023Pooled it
- Sex-specific impact of early life stress on adult lung inflammatory response after LPS and Poly I:C exposures.Brain, behavior, & immunity - health · 2026Article
- Antimicrobial potential of compounds from the MMV pandemic response box and COVID box against carbapenem-resistant Acinetobacter baumannii.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Recent advances in host models in studying virulence factors and pathogenesis ofFrontiers in cellular and infection microbiology · 2025Review
- Predatory bacteria can intensify lung-injury in a multidrug-resistantFrontiers in microbiology · 2025Article
- Multidrug resistantCurrent research in microbial sciences · 2025Review
- Experimental evolution under different nutritional conditions changes the genomic architecture and virulence of Acinetobacter baumannii.Communications biology · 2024Article
- The aryl hydrocarbon receptor and FOS mediate cytotoxicity induced by Acinetobacter baumannii.Nature communications · 2024Article
- Preparation, Optimization, and Anti-Pulmonary Infection Activity of Casein-Based Chrysin Nanoparticles.International journal of nanomedicine · 2024Article
- Exploring Roles of the Polysaccharide Capsule in Pathogenesis of HypervirulentAntibiotics (Basel, Switzerland) · 2023Article
- Enhanced activity of Ellagic acid in lipid nanoparticles (EA-liposomes) againstSaudi journal of biological sciences · 2023Article
- TonB-Dependent Receptor Protein Displayed on Spores ofVaccines · 2023Article
- Enhanced Vulnerability of Diabetic Mice to HypervirulentPathogens (Basel, Switzerland) · 2023Article
- Mouse Tissue-Resident Peritoneal Macrophages in Homeostasis, Repair, Infection, and Tumor Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Outer Membrane Vesicle-Coated Nanoparticle Vaccine Protects AgainstAdvanced nanobiomed research · 2023Article
- Safety and immunogenicity of a new glycoengineered vaccine against Acinetobacter baumannii in mice.Microbial biotechnology · 2022Article
- Neutrophil and Macrophage Response in Acinetobacter Baumannii Infection and Their Relationship to Lung Injury.Frontiers in cellular and infection microbiology · 2022Review
- Replacement of the Dominant ST191 Clone by ST369 Among Carbapenem-ResistantFrontiers in microbiology · 2022Article
- Antimicrobial, Immunomodulatory and Anti-Inflammatory Potential of Liposomal Thymoquinone: Implications in the Treatment of Bacterial Pneumonia in Immunocompromised Mice.Biomedicines · 2021Article
- Facing the challenges of multidrug-resistantHuman vaccines & immunotherapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii infection has become a major cause of healthcare-associated infection and a critical pathogen in the WHO antimicrobial resistance research and development priority list. Catheter-related septicemia is one of the major clinical manifestations of A. baumannii infection associated with high morbidity and mortality. In this study, we used a clinical A. baumannii strain (LAC-4) that is hypervirulent to immunocompetent C57BL/6 and BALB/c mice and established a mouse model of intraperitoneal (i.p.) A. baumannii infection. Our study showed that i.p. LAC-4 infection of C57BL/6 and BALB/c mice induces a lethal or sublethal infection with high bacterial burdens in peritoneal cavity, blood and tissues and the infected mice either succumbed to the infection within 24 hours or completely recovered from the infection. The infection induces acute peritoneal recruitment of neutrophils and other innate immune cells, and the local and systemic production of proinflammatory cytokines and chemokines (IL-1β, IL-5, IL-6, TNF-α, RANTES, MIP-1β, MCP-1, KC and IL-10). Mechanistic studies suggest an important role of macrophages in the host innate defense in this model in that in vitro stimulation of peritoneal macrophages with killed LAC-4 induced a similar pattern of cytokine/chemokine responses to those in the infected mice, and depletion of peritoneal macrophages rendered the mice significantly more susceptible to the infection. Thus, this mouse infection model will provide an alternative and useful tool for future pathogenesis studies of A. baumannii-associated septicemia and identification and characterization of important virulence factors, as well as serve as a surrogate model for rapid evaluation of novel therapeutics and vaccines for this emerging infectious agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.